Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers… (NCT06259019) | Clinical Trial Compass
RecruitingNot Applicable
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
United Kingdom300 participantsStarted 2023-09-14
Plain-language summary
The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest. Using the data generated from extensive analysis of the blood samples, key biomarker data will be generated that will close a knowledge gap and facilitate the development of tailored treatments for coronary artery disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. ≥18 years of age, have capacity and be willing to provide informed consent to participate
✓. Clinical evidence of obstructive coronary artery disease and be scheduled for either:
✓. Elective coronary angiography +/- proceed for stable angina OR
✓. Elective PCI for stable angina with known bystander disease OR
✓. Angiography +/- proceed for Troponin negative unstable angina
Exclusion criteria
✕. Myocardial Infarction within 30 days of procedure.
✕. Immunocompromised or receiving immunosuppressant therapy.
✕. Any active disease that in the opinion of the investigator makes the subject unsuitable for the research procedure or subject life expectancy less than 1 year.